The Chronic Leukemia Working Party of the EBMT has collected data on 118 patients of median age 24 years (range 0.3 to 53 years) who underwent an allogeneic bone marrow transplantation from unrelated donors for treatment of MDS or secondary AML (RA/RARS, n = 24; RAEB, n = 26; RAEB-t, n = 34; CMML, n = 12; sAML, n = 22) between 1986 and 1996. The data were reported by 49 EBMT centers. Thirtyfour of 118 patients are alive, relapse was the cause of death in 19 of 84 patients and the remaining patients died of transplant-related mortality. For the whole group the actuarial probability of survival at 2 years is 28%, disease-free survival 28%, relapse risk 35% and transplant-related mortality is 58%. The transplantrelated mortality is significantly influenced by the age of the recipient (Ͻ18 years 40%, 18-35 years 61%, Ͼ35 years 81%). The relapse rate after BMT is influenced by FAB classification of the disease at BMT. Patients with a low blast count (RA, RAEB) have a lower probability of relapse (13%, 15%) compared to patients with RAEB-t or sAML (29%, 45%). Furthermore, we found evidence of a graft-versus-leukemia effect in MDS/sAML. Patients with acute GVHD, grade II-IV, had a probability of relapse of 26% vs 42% in patients with no acute GVHD or grade I only. Allogeneic transplantation with an HLA-matched, unrelated donor may be offered to younger patients (age Ͻ35 years) with poor risk myelodysplasia or secondary AML. Keywords: unrelated BMT; MDS; sAML Myelodysplastic syndromes (MDS) are acquired clonal disorders of the hematopoietic stem cell characterized by ineffective hematopoiesis and progressive peripheral cytopenias. Infections due to neutropenia and thrombocytopenic bleeding are the most frequent causes of death. Ten to 40%
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Correspondence: Prof Dr med R Arnold, University Hospital Charité, Medical Clinic II, Schumannstr 20/21, 10117 Berlin, Germany Received 5 June 1997; accepted 10 February 1998 of these patients will proceed to acute myeloid leukemia (AML). 1 Therapies for MDS, using low-dose cytostatic agents, growth factors or other substances aiming at differentiation induction, is capable of prolonging survival and improving quality of life in some patients, but the overall benefit is limited. Long-term benefit, however, can only be achieved by eradication of the abnormal clone and restoration of normal hematopoiesis. Treatment of MDS with AML-type chemotherapy regimens may induce complete remissions with wide ranges (15-61%). 2 However, duration of remission is usually short and overall survival rates at 3 years are 7%. 3 Allogeneic marrow transplantation offers a potentially curative treatment for MDS. Actuarial diseasefree survival (DFS) ranges between 35 and 45% at 2 to 4 years after BMT. [4] [5] [6] [7] [8] About 30% of younger patients with MDS/sAML will have an HLA-identical sibling donor and about 5% a one HLA locus mismatched family donor. Increasing size of the voluntary unrelated donor registries facilitates the identification of matched unrelated donors for about 75% of patients. Data on unrelated BMT in MDS/sAML on larger patient groups are rare. 9, 10 In this report we describe the results of an EBMT survey of 118 patients with MDS and sAML, who underwent unrelated BMT between 1986 and 1996.
Patients and methods
The Chronic Leukemia Working Party of the EBMT (based in Leiden) has collected data on 118 patients who underwent an allogeneic bone marrow transplantation from an unrelated donor for treatment of MDS or secondary AML between 1986 and 1996. The data were reported by 49 EBMT centers.
Clinical characteristics of the 118 patients transplanted
Median age was 24 years (0.3-53). Sixty-four patients were males, 54 patients females. The disease classification, at BMT was reported as follows: refractory anemia with or without ringed sideroblasts (RA/RARS) n = 24; refractory anemia with excess blasts (RAEB) n = 26; refractory ane-mia with excess blasts in transformation (RAEB-t) n = 34; chronic myelomonocytic leukemia (CMML) n = 12; secondary acute myeloid leukemia (sAML) n = 22. Five of 34 patients with RAEB-t were in first CR as were six of 22 patients with sAML. Blood counts, blood and marrow smears were not reviewed.
Donor selection
One hundred and five unrelated donor recipient pairs were HLA-A, -B and -DR identical by the standard HLA typing available at the time of donor selection. In the earlier part of the studies, HLA-typing was performed by serology and more recently class II-typing included oligotyping. Thirteen patients were transplanted with a 1 or 2 HLA-locus (minor) mismatch donor.
Conditioning regimens
Sixty-nine patients received total body irradiation and chemotherapy, 30 patients received chemotherapy with or without serotherapy and data on conditioning are unavailable for 19 patients.
GVHD prophylaxis
The 49 reporting EBMT centers used institutional GVHD prophylaxis protocols (cyclosporin A alone n = 8, MTX n = 2, CsA + MTX n = 25, other combinations n = 44, T cell depletion n = 36). For three patients data were missing.
Statistical analysis
Data were analyzed at February 1997. The methods of time to event analysis from BMT were used. Survival, diseasefree survival (DFS), relapse risk and transplant-related mortality (TRM) curves were calculated by the method of Kaplan and Meier. Univariate comparisons were made using the log rank test.
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Results
Engraftment
Fourteen out of 118 patients had no engraftment, four patients had secondary graft failure and 81 patients engrafted permanently. For 19 patients data were missing.
GVHD
Sixty-five of 100 evaluable patients had no acute GVHD or grade I. Forty-seven patients developed acute GVHD, grade II-IV. Sixty-two of 118 patients survived Ͼ100 days post-BMT and were evaluable for the occurrence of chronic GVHD. Information was obtained for 60/62 patients.
Thirty-seven of 60 patients had no chronic GVHD. Twenty-three of 60 patients developed cGVHD, limited disease in 15 patients, extensive disease in eight patients.
Survival and relapse after BMT
Eighty-four patients have died. Relapse was the cause of death in 19 patients, and 65 patients died of transplantrelated mortality. The causes of death were GVHD n = 16, interstitial pneumonia n = 14, other infections n = 14, others n = 21. For the 34 patients alive, the median follow-up was 20 months (range 1-89).
Twenty-one of 118 patients relapsed. Two out of 21 patients are still alive. Ninety-seven patients were reported to have no evidence of underlying disease at last contact. For the whole patient group (n = 118), the actuarial probabilities at 2 years of survival, DFS, relapse and TRM are 28, 28, 35 and 58%, respectively (Figure 1 ).
Univariant analysis of prognostic factors
Stage of disease at BMT: Stage of disease had no significant influence on survival, disease-free survival and treatment-related mortality. The relapse risk was significantly lower when patients had been transplanted for RA/RARS and RAEB (P Ͻ 0.01, Table 1 ).
Age: Age had a major impact on the results of BMT with unrelated donors. The survival and disease-free survival were significantly lower when the transplant was performed for a patient older than 35 years. This was mainly due to significantly increased transplant-related mortality. The TRM at 2 years was 40% below 18 years, 61% when the age of the recipient was between 18-35 years, but 81% when the recipient was older than 35 years ( Figure 2 ).
Interval between diagnosis and BMT:
The interval between diagnosis and transplant was a major factor for treatment outcome. Patients transplanted within 6 months after diagnosis had a DFS of 55%, compared to a DFS of 16% when transplants were undertaken more than 12 months after diagnosis. This was due to an increased TRM.
Graft-versus-host disease:
GVHD had no significant influence on treatment outcome, although the relapse rate was significantly reduced in patients with grade 2 to 4 aGVHD (Figure 3) . Chronic GVHD had no significant influence on relapse (Table 1) .
Discussion
Allogeneic BMT is the treatment of choice in the majority of young patients with MDS or sAML who have a histo- compatible sibling. Large series of patients have been reported from Seattle and Duarte. 7, 8 The Chronic Leukemia Working Party of the EBMT has collected data on several hundreds of patients transplanted for myelodysplasia and the first analysis was reported in 1990.
5 Two-thirds of the patients with MDS who may benefit from allogeneic BMT lack a suitable family donor. Increasing size of the donor registries has made allogeneic BMT with an unrelated donor a realistic alternative. Reported data are scarce. We report here the largest number of unrelated transplants in patients with MDS and sAML.
As reported by the NMDP and a single center study from Seattle, we can show that unrelated bone marrow transplantation cures a certain proportion of patients, but all three studies show a high rate of transplant-related mortality. 9, 10 Transplant-related mortality is clearly dependent on the age of the recipient. Older age was significantly associated with an increased risk of death from causes other than relapse. Longer disease duration was also associated with an increased transplant-related mortality. Since all three studies were initiated in 1986/1987, progress in donor selection and better infection/GVHD prophylaxis may have improved the results and may further improve treatment results in the near future.
Relapse after MUD BMT is dependent on the disease status at BMT. In patients with a lower blast count (RA, RAEB) the relapse risk is 13% and 15%, respectively, which is significantly less than the relapse risk for patients who progressed to RAEB-t or sAML (29% and 45%, respectively). In our patient group we found evidence for a graft-versus-leukemia effect. Patients with acute GVHD, grade II-IV had a relapse probability of 26% compared to 42% in patients with grade 0-I. Chronic GVHD had no influence on relapse. We observed one late relapse beyond 48 months after BMT. The method of GVHD prophylaxis, eg T cell depletion vs no T cell depletion had no significant influence on relapse after BMT, probably due to the small numbers of patients and the variety of T cell depletion methods used.
The indication for MUD BMT is now established in younger patients with RA, RAEB, RAEB-t, CMML and sAML. Donor search should be initiated early in the course of the disease. Patients with RA/RARS Ͻ18 years might proceed immediately to MUD BMT. For older patients, indication for MUD BMT is given when increasing transfusion frequency and symptoms of cytopenia, eg infections occur.
In most institutions, patients with RAEB, RAEB-T and sAML will receive chemotherapy first. Thereafter, patients Ͻ18 years should undergo MUD BMT immediately. In older patients alternative treatment strategies to MUD BMT are possible for the minority of patients who achieved first complete remission and autologous BMT is a reasonable strategy.
